PCNA、P16蛋白在卵巢癌组织中的表达及其临床价值的探讨Expressions of PCNA, P16 in ovarian tumor and their clinical significance
袁碧波,张士伟,孙保存
摘要(Abstract)：
目的：研究PCNA、P16蛋白在卵巢癌中的表达及临床价值。方法：应用免疫组化法检测89份卵巢癌组织PCNA、P16蛋白的表达。结果：PCNA表达在上皮性，中、低分化以及晚期卵巢癌中的表达显著高于非上皮性，高分化及早期卵巢癌（P＜0．05），PCNA表达与残存癌灶大小、是否发生淋巴结转移无关（P＞0．05）。在晚期、残存癌灶≥2cm的卵巢癌中P16蛋白的表达明显低于早期、残存癌灶＜2cm者（P＜0．05）；P16蛋白表达与组织类型、组织分化、淋巴结有无转移无关（P＜0．05）。生存分析表明，PCNA、P16蛋白尚不能作为卵巢癌的独立预后因素。结论：肿瘤细胞的过度增殖在卵巢癌的发生、发展中起一定作用。P16蛋白表达的缺失与卵巢癌的进展有关。测定卵巢癌组织P16、PCNA的表达，对客观评价肿瘤的增殖状态，进行“个体化”治疗有指导价值。
关键词(KeyWords)： 卵巢肿瘤;细胞增殖;增殖细胞核抗原;蛋白质P16;免疫组织化学
基金项目(Foundation):
作者(Author): 袁碧波,张士伟,孙保存
DOI: 10.13283/j.cnki.xdfckjz.1999.04.003
参考文献(References)：
- 1. Hirama T, Koeffler HP. Role of the cyclin-dependent kinase inhibitor in the development of cancer.Blood, 1995, 86 (3 ): 841
- 2. Kurki P,Vanderlaa M,Ddolbeare T,et al. Expression of proliferating cell nuclear antigen (PCNA) /cyclinduring the cell cycle. Exp Cell Res, 1986; 166 (1): 209
- 3. Ghazizadeh M,Sasaki Y,Araki T,et al. Prognostic value of proliferative actlvity of ovarian carcinoma asrevea1ed by PCNA and AgNOR analyses. Am J Clin Pathol, 1997; 107(4): 451
- 4. Thomas H, Nasim MM, Sarraf CE, et al. Proliferating cell nuclear antigen (PCNA) immunostaining-aprognostic factor in ovarian cancer? Br J Cancer, 1995; 71:357
- 5. Nakopoulou L,Janinis J,Panagos G,et al. The immunohistochemical expression of PCNA in malignantand benign epithelial ovarian neoplasms and correlation with prognoais. Eur J Cancer, 1993; 29(11): 1599
- 6. Altavilla G, Marchetti M, Padovan P, et al. Predictive value of proliferative cellular nuclear antigen(PCNA)and Ki-67 antigen in advanced stage serous papilliferous ovarian cancer. Eur J Gynaecol Oncol,1996; 17(6)524
- 7. Marxs J. New tumor suppressor may rival p53. Science, 1994; 264: 344
- 8. Shih YC,Kerr J,Lin J,et al. Rare mutation and no hypermethylation at CDK2 locus in epithelial ovariantumor. Int J Cancer, 1997; 70(5l): 508
- 9. Dong Y, Walsh M, Mcguckin M, et al. Increased expression of cyclindependent kinase inhibitor2(CDKN2A)gene product p16INK4A in ovarian cancer is associated with pxogression and unfavorableprognosis. Int J Cancer, 1997; 71(1): 57
- 10. Ichikawa Y,Yoshida S,Koyama Y,et al. Inactivation of p16/CDKN2 and p15/MTS2 genes in differenthistological types and clinical stagcs of primary ovarian tumors. Int J Cancer, 1996; 69 (6): 466